Login
$MBX
$53.12 -$2.82 (5.04%) Live

$MBX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway

22 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed P...

27 Aug 2026 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

06 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting

13 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

12 Jun 2026 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

05 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under Item 5.07 below, the Company's stockholders approved the election of two Class II dire...

11 May 2026 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

07 May 2026 8-K: Results of Operations and Financial Condition

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026

12 Mar 2026 8-K: Results of Operations and Financial Condition

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA

09 Mar 2026 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

27 Feb 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

05 Feb 2026 8-K: Other Events

On February 4, 2026, MBX Biosciences, Inc. (the “Company”), closed on the sale and issuance of an aggregate of 2,250,986 shares of its common stock (the "Shares") at a volume weighted average price per share of $38.76 for gross proceeds ...

22 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the trea...

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026

06 Nov 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP)

26 Sep 2025 8-K: Entry into a Material Definitive Agreement

As Representatives of the several Underwriters listed in Schedule 1 hereto

22 Sep 2025 8-K: Regulation FD Disclosure; Other Events

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

04 Sep 2025 8-K: Regulation FD Disclosure; Other Events

Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291

07 Aug 2025 8-K: Results of Operations and Financial Condition

Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support